Alpinate Oxyphyllae Fructus Inhibits IGFII-Related Signaling Pathway to Attenuate Ang II-Induced Pathological Hypertrophy in H9c2 Cardiomyoblasts

被引:10
|
作者
Tsai, Chuan-Te [1 ]
Chang, Yung-Ming [1 ,2 ,3 ]
Lin, Shu-Luan [4 ]
Chen, Yueh-Sheng [5 ]
Yeh, Yu-Lan [7 ,8 ]
Padma, Viswanadha Vijaya [9 ]
Tsai, Chin-Chuan [2 ,3 ]
Chen, Ray-Jade [10 ]
Ho, Tsung-Jung [5 ]
Huang, Chih-Yang [5 ,6 ,11 ]
机构
[1] IPT Biotechnol Co Ltd, Taichung, Taiwan
[2] I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan
[3] E DA Hosp, Chinese Med Dept, Kaohsiung, Taiwan
[4] IPT Lukang Chinese Med Clin, Changhua, Taiwan
[5] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan
[6] China Med Univ, Grad Inst Basic Med Sci, 91 Hsueh Shih Rd, Taichung 40402, Taiwan
[7] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan
[8] Jen Teh Jr Coll Med Nursing & Management, Dept Med Technol, Miaoli, Taiwan
[9] Bharathiar Univ, Dept Biotechnol, Coimbatore, Tamil Nadu, India
[10] Taipei Med Univ, Sch Med, Dept Surg, Coll Med, Taipei, Taiwan
[11] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan
关键词
hypertrophy; alpinate oxyphyllae fructus; H9c2; Cell; angiotensin II; GROWTH-FACTOR-II; HYPERTENSIVE-RAT HEART; G-ALPHA-Q; ANGIOTENSIN-II; CARDIAC-HYPERTROPHY; PROTOCATECHUIC ACID; MYOCARDIAL-INFARCTION; 6-PHOSPHATE RECEPTOR; HISTONE ACETYLATION; CELL HYPERTROPHY;
D O I
10.1089/jmf.2014.3340
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Angiotensin II (Ang II) is a very important cardiovascular disease inducer and may cause cardiac pathological hypertrophy and remodeling. We evaluated a Chinese traditional medicine, alpinate oxyphyllae fructus (AOF), for therapeutic efficacy for treating Ang II-induced cardiac hypertrophy. AOF has been used to treat patients with various symptoms accompanying hypertension and cerebrovascular disorders in Korea. We investigated its protective effect against Ang II-induced cytoskeletal change and hypertrophy in H9c2 cells. The results showed that treating cells with Ang II resulted in pathological hypertrophy, such as increased expression of transcription factors NFAT-3/p-NFAT-3, hypertrophic response genes (atrial natriuretic peptide [ANP] and b-type natriuretic peptide [BNP]), and G alpha q down-stream effectors (PLC beta 3 and calcineurin). Pretreatment with AOF (60-100 mu g/mL) led to significantly reduced hypertrophy. We also found that AOF pretreatment significantly suppressed the cardiac remodeling proteins, metalloproteinase (MMP9 and MMP2), and tissue plasminogen activator (tPA), induced by Ang II challenge. In conclusion, we provide evidence that AOF protects against Ang II-induced pathological hypertrophy by specifically inhibiting the insulin-like growth factor (IGF) II/IIR-related signaling pathway in H9c2 cells. AOF might be a candidate for cardiac hypertrophy and ventricular remodeling prevention in chronic cardiovascular diseases.
引用
收藏
页码:300 / 309
页数:10
相关论文
共 50 条
  • [1] Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells
    Chang, Yung-Ming
    Velmurugan, Bharath Kumar
    Kuo, Wei-Wen
    Chen, Yueh-Sheng
    Ho, Tsung-Jung
    Tsai, Chuan-Te
    Ye, Chi-Xin
    Tsai, Chang-Hai
    Tsai, Fuu-Jen
    Huang, Chih-Yang
    BIOMEDICINE-TAIWAN, 2013, 3 (04): : 148 - 152
  • [2] EGCG inhibits Angiotensin II-induced cardiac hypertrophy in H9C2 via activate HIPPO signaling pathway
    Ma, Yuan
    Li, Jue
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (16) : C82 - C82
  • [3] Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
    Abdulrahman, Nabeel
    Ibrahim, Meram
    Joseph, Jensa Mariam
    Elkoubatry, Hanan Mahmoud
    Al-Shamasi, Al-Anood
    Rayan, Menatallah
    Gadeau, Alain Pierre
    Ahmed, Rashid
    Eldassouki, Hussein
    Hasan, Anwarul
    Mraiche, Fatima
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2022, 477 (06) : 1865 - 1872
  • [4] Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
    Nabeel Abdulrahman
    Meram Ibrahim
    Jensa Mariam Joseph
    Hanan Mahmoud Elkoubatry
    Al-Anood Al-Shamasi
    Menatallah Rayan
    Alain Pierre Gadeau
    Rashid Ahmed
    Hussein Eldassouki
    Anwarul Hasan
    Fatima Mraiche
    Molecular and Cellular Biochemistry, 2022, 477 : 1865 - 1872
  • [5] Alpinate Oxyphyllae Fructus (Alpinia Oxyphylla Miq) Extracts Inhibit Angiotensin-II Induced Cardiac Apoptosis in H9c2 Cardiomyoblast Cells
    Chang, Yung-Ming
    Tsai, Chuan-Te
    Wang, Chiun-Chuang Roger
    Chen, Yueh-Sheng
    Lin, Yueh-Min
    Kuo, Chia-Hua
    Tzang, Bor-Show
    Chen, Ray-Jade
    Tsai, Fuu-Jen
    Huang, Chih-Yang
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2013, 77 (02) : 229 - 234
  • [6] Protective Effects of Nanoceria against Mitochondrial Dysfunction and Angiotensin II-Induced Hypertrophy in H9c2 Cardiomyoblasts
    Gul, Rukhsana
    Dar, Mushtaq A.
    Nawaz, Shahid
    Alfadda, Assim A.
    ANTIOXIDANTS, 2023, 12 (04)
  • [7] Inhibition of eNOS Partially Blunts the Beneficial Effects of Nebivolol on Angiotensin II-Induced Signaling in H9c2 Cardiomyoblasts
    Gul, Rukhsana
    Alsalman, Nouf
    Alfadda, Assim A.
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2022, 44 (05) : 2139 - 2152
  • [8] 20-HETE mediates Ang II-induced cardiac hypertrophy via ROS and Ca2+ signaling in H9c2 cells
    Han, Jingyi
    Li, Jiaojiao
    Liu, Lianlian
    Li, Kaiyuan
    Zhang, Chun
    Han, Yong
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [9] Epigallocatechin-3-gallate inhibits angiotensin II-induced cardiomyocyte hypertrophy via regulating Hippo signaling pathway in H9c2 rat cardiomyocytes
    Ma, Yuan
    Hu, Yongjia
    Wu, Jiawen
    Wen, Junru
    Li, Sen
    Zhang, Lijuan
    Zhang, Jie
    Li, Yanfei
    Li, Jue
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2019, 51 (04) : 422 - 430
  • [10] MiR-208a-3p aggravates autophagy through the PDCD4-ATG5 pathway in Ang II-induced H9c2 cardiomyoblasts
    Wang, Li
    Ye, Nan
    Lian, Xiaoyu
    Peng, Fei
    Zhang, Hexi
    Gong, Hui
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 98 : 1 - 8